…
Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. It operates through two segments, Product and Service. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. The AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. It also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; AEM EndoShield 2 burn protection systems; AEM 2X enTouch scissors; and electrical engineering activities for external entities. In addition, the company markets AEM monitor product line that is used in conjunction with AEM instruments. It sells its products through a network of direct and independent sales representatives. The company was formerly known as Electroscope Inc and changed its name to Encision Inc. in August 2000. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Encision Inc is a small medical-device company that develops and sells electrosurgical instruments and accessories for minimally invasive and open surgical procedures. Long-term growth drivers may include aging populations, wider adoption of minimally invasive surgery and product or geographic expansion that could support recurring consumable sales, making the company attractive as exposure to a specialized surgical niche.
Principal risks include limited public disclosure and thin trading liquidity, reliance on a narrow product portfolio and hospital procurement cycles, regulatory and reimbursement uncertainty, and competition from larger device manufacturers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Income before tax | -0.72M | -0.22M | -0.69M | -0.32M | -0.07M |
| Net income | -0.72M | -0.22M | -0.69M | -0.37M | 0.46M |
| Selling general administrative | - | 1.40M | 1.52M | 1.49M | 1.38M |
| Selling and marketing expenses | - | 1.69M | 1.63M | 2.03M | 2.08M |
| Gross profit | 2.71M | 3.51M | 3.14M | 4.03M | 3.79M |
| Reconciled depreciation | - | 0.08M | 0.09M | 0.09M | 0.11M |
| Ebit | -0.64M | -0.18M | -0.63M | -0.30M | -0.59M |
| Ebitda | -0.54M | -0.10M | -0.54M | -0.22M | -0.48M |
| Depreciation and amortization | 0.09M | 0.08M | 0.09M | 0.09M | 0.11M |
| Operating income | -0.64M | -0.17M | -0.64M | -0.30M | -0.59M |
| Other operating expenses | 6.42M | 6.73M | 7.23M | 7.65M | 8.26M |
| Interest expense | 0.06M | 0.04M | 0.06M | 0.02M | 0.01M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | - | - | - | 0.53M |
| Net interest income | - | -0.04M | -0.06M | -0.02M | 0.53M |
| Income tax expense | - | - | 0.00M | 0.04M | -0.53M |
| Total revenue | 5.78M | 6.56M | 6.59M | 7.35M | 7.67M |
| Total operating expenses | 3.35M | 3.68M | 3.78M | 4.34M | 4.38M |
| Cost of revenue | 3.07M | 3.04M | 3.45M | 3.32M | 3.88M |
| Total other income expense net | -0.08M | -0.05M | -0.05M | -0.02M | 0.53M |
| Net income from continuing ops | - | -0.22M | -0.69M | -0.32M | -0.07M |
| Net income applicable to common shares | - | - | - | -0.32M | -0.07M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Total assets | 3.70M | 3.67M | 3.81M | 4.13M | 4.79M |
| Intangible assets | - | 0.17M | 0.16M | 0.16M | 0.18M |
| Other current assets | 0.09M | 0.09M | 0.09M | 0.12M | 0.12M |
| Total liab | 2.27M | 2.02M | 1.98M | 1.64M | 2.05M |
| Total stockholder equity | 1.43M | 1.65M | 1.83M | 2.50M | 2.75M |
| Other current liab | 0.23M | 0.27M | 0.25M | 0.30M | 0.32M |
| Common stock | 24.92M | 24.42M | 24.37M | 24.35M | 24.27M |
| Capital stock | - | 24.42M | 24.37M | 24.35M | 24.27M |
| Retained earnings | -23.48M | -22.77M | -22.55M | -21.85M | -21.53M |
| Other assets | - | - | - | 0.05M | 0.03M |
| Cash | 0.25M | 0.26M | 0.04M | 0.19M | 0.95M |
| Total current liabilities | 1.41M | 1.58M | 1.22M | 1.13M | 1.28M |
| Current deferred revenue | - | 0.04M | - | - | - |
| Net debt | 1.45M | 1.06M | 1.29M | 0.89M | 0.20M |
| Short term debt | 0.84M | 0.87M | 0.57M | 0.57M | 0.38M |
| Short long term debt | - | 0.44M | 0.20M | 0.22M | 0.02M |
| Short long term debt total | 1.70M | 1.31M | 1.33M | 1.08M | 1.15M |
| Property plant equipment | - | - | - | 0.80M | 0.98M |
| Total current assets | 2.30M | 2.61M | 2.43M | 3.12M | 3.60M |
| Net tangible assets | - | - | - | 2.33M | 2.57M |
| Net receivables | 0.65M | 0.79M | 0.89M | 0.92M | 0.95M |
| Long term debt | - | 0.18M | 0.07M | 0.27M | 0.21M |
| Inventory | 1.32M | 1.48M | 1.40M | 1.90M | 1.58M |
| Accounts payable | 0.34M | 0.35M | 0.35M | 0.25M | 0.58M |
| Non currrent assets other | 0.08M | 0.07M | 0.07M | 0.05M | 0.03M |
| Non current assets total | 1.40M | 1.06M | 1.38M | 1.01M | 1.19M |
| Capital lease obligations | - | 0.70M | 1.07M | 0.59M | 0.93M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Investments | - | -0.08M | -0.04M | -0.18M | -0.04M |
| Change to liabilities | - | - | - | -0.32M | 0.19M |
| Total cashflows from investing activities | -0.05M | -0.08M | -0.04M | -0.18M | -0.04M |
| Net borrowings | - | 0.35M | -0.22M | 0.26M | -0.01M |
| Total cash from financing activities | 0.42M | 0.35M | -0.25M | 0.28M | -0.04M |
| Change to operating activities | - | - | - | -0.06M | -0.21M |
| Net income | -0.72M | -0.22M | -0.69M | -0.32M | -0.07M |
| Change in cash | -0.01M | 0.21M | -0.15M | -0.76M | -0.52M |
| Begin period cash flow | 0.26M | 0.04M | 0.19M | 0.95M | 1.47M |
| End period cash flow | 0.25M | 0.26M | 0.04M | 0.19M | 0.95M |
| Total cash from operating activities | -0.38M | -0.05M | 0.14M | -0.86M | -0.44M |
| Depreciation | 0.09M | 0.08M | 0.09M | 0.09M | 0.11M |
| Other cashflows from investing activities | - | -0.03M | -0.02M | - | - |
| Change to inventory | 0.16M | -0.09M | 0.48M | -0.33M | -0.10M |
| Change to account receivables | 0.14M | 0.10M | 0.03M | 0.03M | 0.16M |
| Other cashflows from financing activities | - | - | -0.03M | 0.28M | -0.03M |
| Change to netincome | - | - | - | 0.07M | -0.53M |
| Capital expenditures | 0.04M | 0.08M | 0.04M | 0.18M | 0.04M |
| Change in working capital | 0.24M | 0.03M | 0.69M | -0.69M | 0.04M |
| Stock based compensation | - | 0.05M | 0.05M | 0.05M | 0.04M |
| Other non cash items | -0.00M | 0.00M | 0.01M | -0.61M | -0.57M |
| Free cash flow | -0.43M | -0.13M | 0.11M | -1.04M | -0.48M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ECIA Encision Inc |
- -% |
0.01 | - | 16.53 | 0.11 | 0.38 | 0.34 | -11.18 |
| ISRG Intuitive Surgical Inc |
-8.88 1.97% |
440.65 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-2.56 1.26% |
200.18 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-1.98 1.94% |
99.87 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
0.83 0.39% |
215.35 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. It operates through two segments, Product and Service. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. The AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. It also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; AEM EndoShield 2 burn protection systems; AEM 2X enTouch scissors; and electrical engineering activities for external entities. In addition, the company markets AEM monitor product line that is used in conjunction with AEM instruments. It sells its products through a network of direct and independent sales representatives. The company was formerly known as Electroscope Inc and changed its name to Encision Inc. in August 2000. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.
| Name | Title | Year Born |
|---|---|---|
| Mr. Gregory J. Trudel | CEO, Pres & Director | 1961 |
| Mr. David W. Newton | Co-Founder, VP of Technology & Director | 1947 |
| Mr. Vern D. Kornelsen | Co-Founder & Independent Director | 1933 |
| Mr. Robert H. Fries | Contract CFO & Independent Director | 1949 |
| Mr. Brian Jackman | VP of Marketing | 1982 |
| Mr. Peter Geary | COO & VP of Operations | 1958 |
| Ms. Mala Ray | VP, Controller, Treasurer & Corp. Sec. | 1959 |
| Mr. Robert H. Fries | Interim President, CEO & Director | 1949 |
| Mr. Jason E. Johnson | Vice President of Sales | 1975 |
| Mr. David W. Newton | Co-Founder | 1947 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.